Ocular Therapeutix, Inc. (NASDAQ:OCUL) Position Boosted by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 22.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 270,422 shares of the biopharmaceutical company's stock after buying an additional 48,763 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.17% of Ocular Therapeutix worth $2,309,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Atlas Capital Advisors Inc. acquired a new stake in shares of Ocular Therapeutix in the 4th quarter worth approximately $43,000. AlphaQuest LLC purchased a new stake in Ocular Therapeutix in the 4th quarter worth approximately $53,000. Tower Research Capital LLC TRC increased its stake in Ocular Therapeutix by 2,045.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 8,446 shares during the last quarter. Walleye Capital LLC purchased a new position in shares of Ocular Therapeutix during the 4th quarter worth about $90,000. Finally, XTX Topco Ltd acquired a new position in shares of Ocular Therapeutix in the 4th quarter valued at $99,000. Institutional investors and hedge funds own 59.21% of the company's stock.

Ocular Therapeutix Stock Up 0.7%

Ocular Therapeutix stock traded up $0.05 during midday trading on Friday, hitting $7.22. 1,640,879 shares of the stock were exchanged, compared to its average volume of 1,399,226. Ocular Therapeutix, Inc. has a 1 year low of $4.79 and a 1 year high of $11.78. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The firm has a market cap of $1.15 billion, a P/E ratio of -5.47 and a beta of 1.51. The company has a 50 day moving average price of $7.41 and a two-hundred day moving average price of $8.15.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The business had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. On average, sell-side analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on OCUL shares. William Blair started coverage on Ocular Therapeutix in a research note on Tuesday, April 8th. They issued an "outperform" rating on the stock. JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price objective for the company. Needham & Company LLC reduced their target price on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Finally, HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.25.

Insiders Place Their Bets

In related news, Director Richard L. Md Lindstrom acquired 10,000 shares of the stock in a transaction that occurred on Thursday, May 8th. The stock was purchased at an average cost of $6.96 per share, for a total transaction of $69,600.00. Following the purchase, the director now directly owns 172,704 shares in the company, valued at $1,202,019.84. This represents a 6.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Pravin Dugel sold 21,475 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the sale, the insider now owns 3,520,318 shares in the company, valued at $24,184,584.66. The trade was a 0.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by company insiders.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.